These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 12411222)

  • 41. Premenstrual dysphoria and the serotonin system: pathophysiology and treatment.
    Steiner M; Pearlstein T
    J Clin Psychiatry; 2000; 61 Suppl 12():17-21. PubMed ID: 11041380
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Premenstrual dysphoric disorder: approach and treatment].
    Bianchi-Demicheli F; Lüdicke F; Campana A
    Gynecol Obstet Fertil; 2003 Jan; 31(1):49-54. PubMed ID: 12659785
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Premenstrual Dysphoric Disorder.
    Lanza di Scalea T; Pearlstein T
    Psychiatr Clin North Am; 2017 Jun; 40(2):201-216. PubMed ID: 28477648
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Premenstrual syndrome and premenstrual dysphoric disorder.
    Biggs WS; Demuth RH
    Am Fam Physician; 2011 Oct; 84(8):918-24. PubMed ID: 22010771
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Selective serotonin reuptake inhibitors for premenstrual syndrome.
    Wyatt KM; Dimmock PW; O'Brien PM
    Cochrane Database Syst Rev; 2002; (4):CD001396. PubMed ID: 12519554
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Response to flumazenil in women with premenstrual dysphoric disorder.
    Le Mellédo JM; Van Driel M; Coupland NJ; Lott P; Jhangri GS
    Am J Psychiatry; 2000 May; 157(5):821-3. PubMed ID: 10784479
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial.
    Miner C; Brown E; McCray S; Gonzales J; Wohlreich M
    Clin Ther; 2002 Mar; 24(3):417-33. PubMed ID: 11952025
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Premenstrual Dysphoric Disorder.
    Lanza di Scalea T; Pearlstein T
    Med Clin North Am; 2019 Jul; 103(4):613-628. PubMed ID: 31078196
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rapid response to fluoxetine in women with premenstrual dysphoric disorder.
    Steinberg EM; Cardoso GM; Martinez PE; Rubinow DR; Schmidt PJ
    Depress Anxiety; 2012 Jun; 29(6):531-40. PubMed ID: 22565858
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of premenstrual dysphoria with selective serotonin re-uptake inhibitors: focus on safety.
    Macdougall M; Steiner M
    Expert Opin Drug Saf; 2003 Mar; 2(2):161-6. PubMed ID: 12904116
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A pilot study to compare fluoxetine, calcium, and placebo in the treatment of premenstrual syndrome.
    Yonkers KA; Pearlstein TB; Gotman N
    J Clin Psychopharmacol; 2013 Oct; 33(5):614-20. PubMed ID: 23963058
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A double-blind trial of four medications to treat severe premenstrual syndrome.
    Diegoli MS; da Fonseca AM; Diegoli CA; Pinotti JA
    Int J Gynaecol Obstet; 1998 Jul; 62(1):63-7. PubMed ID: 9722128
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Premenstrual dysphoric disorder. An overview of diagnosis, epidemiology and therapeutic approaches].
    Lenzinger E; Diamant K; Vytiska-Binstorfer E; Kasper S
    Nervenarzt; 1997 Sep; 68(9):708-18. PubMed ID: 9411273
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Venlafaxine in the treatment of premenstrual dysphoric disorder.
    Freeman EW; Rickels K; Yonkers KA; Kunz NR; McPherson M; Upton GV
    Obstet Gynecol; 2001 Nov; 98(5 Pt 1):737-44. PubMed ID: 11704162
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Diagnostic and therapeutic algorithm for the treatment of premenstrual dysphoric disorder].
    Strkalj Ivezić S; Kusan Jukić M; Tikvica A; Pavicić Baldani D
    Acta Med Croatica; 2010 Jul; 64(3):183-90. PubMed ID: 20922861
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder.
    Atmaca M; Kumru S; Tezcan E
    Hum Psychopharmacol; 2003 Apr; 18(3):191-5. PubMed ID: 12672170
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Premenstrual syndromes.
    Steiner M
    Annu Rev Med; 1997; 48():447-55. PubMed ID: 9046975
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lamotrigine augmentation in premenstrual dysphoric disorder: a case report.
    Sepede G; Martinotti G; Gambi F; Salerno RM; Di Giannantonio M
    Clin Neuropharmacol; 2013; 36(1):31-3. PubMed ID: 23334074
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder.
    Eriksson E; Ekman A; Sinclair S; Sörvik K; Ysander C; Mattson UB; Nissbrandt H
    J Clin Psychopharmacol; 2008 Apr; 28(2):195-202. PubMed ID: 18344730
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patient information. What is premenstrual dysphoric disorder (PMDD)?
    Cleve Clin J Med; 2004 Apr; 71(4):322. PubMed ID: 15117172
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.